Advanced search
Publication Cover
Ultrastructural Pathology Volume 44, 2020 - Issue 2
Submit an article Journal homepage
128
Views
2
CrossRef citations to date
0
Altmetric
Basic Research

MicroRNA-195 vector influence on the development of gradually induced hepatocellular carcinoma in murine model

Eman El-AhwanyImmunology Department, Theodor Bilharz Research Institute, Giza, EgyptView further author information
,
Soheir S. MansyElectron Microscopy Research Department (Pathology), Theodor Bilharz Research Institute, Giza, EgyptView further author information
,
Mona ZoheiryImmunology Department, Theodor Bilharz Research Institute, Giza, EgyptView further author information
,
Lobna MouradBiology Department, American University in Cairo, Cairo, EgyptView further author information
,
Soheir MahmoudParasitology Department, Theodor Bilharz Research Institute, Giza, EgyptView further author information
,
Hoda Abu-TalebEnvironmental Research Department, Theodor Bilharz Research Institute, Giza, EgyptView further author information
,
Moataz HassanienHepato-Gastroenterology Department, Theodor Bilharz Research Institute, Giza, EgyptView further author information
&
Marwa HassanImmunology Department, Theodor Bilharz Research Institute, Giza, EgyptCorrespondence[email protected]
View further author information
 show all
Pages 203-210 | Received 23 Jan 2020, Accepted 16 Mar 2020, Published online: 26 Mar 2020

References

  • Ringelhan M, Pfister D, O’Connor T, et al. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19(3):222–232. doi:10.1038/s41590-018-0044-z.
  • ST O, DA A. Liver resection and surgical strategies for management of primary liver cancer. Cancer Control. 2018;25:1073274817744621.
  • Mansy SS, El-Ahwany E, Mahmoud S, et al. Potential ultrastructure predicting factors for hepatocellular carcinoma in HCV infected patients. Ultrastruct Pathol. 2017;41(3):209–226. doi:10.1080/01913123.2017.1316330.
  • El-Ahwany E, Mourad L, Zoheiry M, et al. MicroRNA-122a as a non-invasive biomarker for HCV genotype 4-related hepatocellular carcinoma in Egyptian patients. Arch Med Sci. 2019;15(6):1454–1461. doi:10.5114/aoms.2019.86621.
  • Horng CT, Huang CW, Yang MY, et al. Nelumbo nucifera leaf extract treatment attenuated preneoplastic lesions and oxidative stress in the livers of diethylnitrosamine-treated rats. Environ Toxicol. 2017;32(11):2327–2340. doi:10.1002/tox.22434.
  • Shang N, Bank T, Ding X, et al. Caspase-3 suppresses diethylnitrosamine-induced hepatocyte death, compensatory proliferation and hepatocarcinogenesis through inhibiting p38 activation. Cell Death Dis. 2018;9(5):558. doi:10.1038/s41419-018-0617-7.
  • Yan JJ, Chang Y, Zhang YN, et al. miR-195 inhibits cell proliferation via targeting AEG-1 in hepatocellular carcinoma. Oncol Lett. 2017;13(5):3118–3126. doi:10.3892/ol.2017.5826.
  • Abdel-Al A, El-Ahwany E, Zoheiry M, et al. miRNA-221 and miRNA-222 are promising biomarkers for progression of liver fibrosis in HCV Egyptian patients. Virus Res. 2018;253:135–139. doi:10.1016/j.virusres.2018.06.007.
  • Wang M, Zhang J, Tong L, et al. MiR-195 is a key negative regulator of hepatocellular carcinoma metastasis by targeting FGF2 and VEGFA. Int J Clin. Exp Pathol. 2015;8(11):14110–14120.
  • Vanheule E, Geerts AM, Van Huysse J, et al. An intravital microscopic study of the hepatic microcirculation in cirrhotic mice models: relationship between fibrosis and angiogenesis. Int J Exp Pathol. 2008;89(6):419–432. doi:10.1111/j.1365-2613.2008.00608.x.
  • Unsal V, Belge-Kurutaş E. Experimental hepatic carcinogenesis: oxidative stress and natural antioxidants. Open Access Maced J Med Sci. 2017;5(5):686–691. doi:10.3889/oamjms.2017.101.
  • Yu X, Zhang Y, Cavazos D, et al. miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer. Cell Death Dis. 2018;9(2):193. doi:10.1038/s41419-017-0219-9.
  • Aravalli RN. Development of MicroRNA therapeutics for hepatocellular carcinoma. Diagnostics (Basel). 2013;3(1):170–191. doi:10.3390/diagnostics3010170.
  • Kota J, Chivukula RR, O’Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137(6):1005–1017. doi:10.1016/j.cell.2009.04.021.
  • Bader AG. miR-34 – a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3:120. doi:10.3389/fgene.2012.00120.
  • Zheng F, Liao YJ, Cai MY, et al. Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets. PLoS Genet. 2015;11(2):e1004873. doi:10.1371/journal.pgen.1004873.
  • Fu MG, Li S, Yu TT, et al. Differential expression of miR-195 in esophageal squamous cell carcinoma and miR-195 expression inhibits tumor cell proliferation and invasion by targeting of Cdc42. FEBS Lett. 2013;587(21):3471–3479. doi:10.1016/j.febslet.2013.08.036.
  • Zhou B, Sun C, Hu X, et al. MicroRNA-195 suppresses the progression of pancreatic cancer by targeting DCLK1. Cell Physiol Biochem. 2017;44(5):1867–1881. doi:10.1159/000485876.
  • Li L, Piontek K, Ishida M, et al. Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model. Hepatology. 2017;65(2):501–514. doi:10.1002/hep.v65.2.
  • Yu S, Jing L, Yin XR, et al. MiR-195 suppresses the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by inhibiting YAP. Oncotarget. 2017;8(59):99757–99771. doi:10.18632/oncotarget.20909.
  • Cao Y, Cao J, Yu B, et al. Berbamine induces SMMC-7721 cell apoptosis via upregulating p53, downregulating survivin expression and activating mitochondria signaling pathway. Exp Ther Med. 2018;15(2):1894–1901. doi:10.3892/etm.2017.5637.
  • Huang YH, Lin KH, Yu JS, et al. Targeting HSP60 by subcutaneous injections of jetPEI/HSP60-shRNA destabilizes cytoplasmic survivin and inhibits hepatocellular carcinoma growth. Mol Carcinog. 2018;57(9):1087–1101. doi:10.1002/mc.22827.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.